Form D · Biotechnology
Avidity Biosciences, Inc.
San Diego, CA · CIK 0001599901
Offering snapshot reported Mar 19, 2024 · SEC filing
- Reported sold
- $400M Offering amount: $400M
- Investors reported
- 45 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Mar 4, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 19, 2024 | Initial | $400,208,765 | No comparison | 45 | SEC filing |
| Nov 13, 2019 | Initial | $100,503,090 | No comparison | 28 | SEC filing |
| Jan 6, 2017 | Initial | $17,971,847 | No comparison | 21 | SEC filing |
| Feb 18, 2014 | Initial | $9,067,850 | No comparison | 36 | SEC filing |
| Feb 18, 2014 | Amendment | $9,067,850 | $0vs Feb 18, 2014 | 36 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $20M (estimated)
- Finders' fees
- $0
- Form D file number
- 021-508060
The compensation payable to the placement agents under the total offering amount is estimated to consist of a cash fee of 5.0% of the total amount sold in Item 13, allocated among the placement agents.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Leerink Partners LLC | 39011 | |
| BofA Securities Inc. | 283942 | |
| Cantor Fitzgerald & Co. | 134 | |
| Chardan Capital Markets, LLC | 120128 |
Source: Form D, filed Mar 19, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Carsten Boess | Director |
| Sarah Boyce | Director, Executive |
| Todd Brady | Director |
| Mark E. Davis | Director |
| W. Michael Flanagan | Executive |
| P. Kent Hawryluk | Executive |
| Noreen Henig | Director |
| Edward Kaye | Director |
| Jean Kim | Director |
| Arthur Levin | Executive |
| Michael Mac Lean | Executive |
| Michael Martin | Director |
| Michael Martin Ph D. | Director |
| Teresa Mc Carthy | Executive |
| Frank Mc Cormick | Director |
| Tamar Thompson | Director |
| Troy Wilson | Director |
| Troy Wilson Ph D., Jd | Director, Executive |
| Roderick Wong | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
10578 Science Center Drive, Suite 125
San Diego, CA, 92121
San Diego, CA, 92121